FDA Grants Breakthrough Therapy Designation to Novartis' Serelaxin (RLX030 …

FDA grants Breakthrough Therapy designation to Novartis' serelaxin (RLX030 …
Filed under: dual diagnosis drug treatment

Another Novartis compound called LCZ696, an angiotensin receptor neprilysin inhibitor, is the first in a new class of dual acting drugs being evaluated for the treatment of chronic heart failure. A robust clinical development program including two …
{Source}